Thiazolidinedione Drug Class List

Drugs in Drug Class: Thiazolidinedione

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Torrent Pharms Ltd	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	202001-001	Feb 13, 2013	AB	RX	No	No
Aurobindo Pharma Ltd	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	200823-002	Feb 13, 2013	AB	RX	No	No
Torrent Pharms Ltd	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	202001-002	Feb 13, 2013	AB	RX	No	No
Macleods Pharms Ltd	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	204802-001	Nov 5, 2015	AB	RX	No	No
Macleods Pharms Ltd	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	204802-002	Nov 5, 2015	AB	RX	No	No
Aurobindo Pharma Ltd	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	200823-001	Feb 13, 2013	AB	RX	No	No
Aiping Pharm Inc	PIOGLITAZONE HYDROCHLORIDE	pioglitazone hydrochloride	TABLET;ORAL	078670-003	Feb 13, 2013	AB	RX	No	No

Market Dynamics and Patent Landscape for Thiazolidinedione Drugs

Last updated: March 3, 2026

What is the Current Market Size and Growth Outlook?

Thiazolidinediones (TZDs) are oral antidiabetic agents primarily used for type 2 diabetes mellitus. The global market for TZD drugs was valued at approximately USD 6.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 3.2% from 2023 to 2030, driven by increasing diabetes prevalence and evolving treatment guidelines.

Major marketed drugs include pioglitazone and rosiglitazone. Use of rosiglitazone declined after safety concerns, particularly cardiovascular risks, leading to its market withdrawal in several countries. Conversely, pioglitazone remains widely used globally but faces regulatory restrictions in some regions due to safety concerns, such as increased risk of bladder cancer.

What Are Key Market Drivers?

• Rising prevalence of type 2 diabetes: An estimated 537 million adults worldwide had diabetes in 2021, expected to reach 643 million by 2030 (IDF, 2021).
• Preference for oral medications: TZDs are differentiated by their efficacy in improving insulin sensitivity.
• Combination therapies: TZDs are combined with metformin, SGLT2 inhibitors, and others, expanding therapeutic options.
• Patent expirations: Several patents related to pioglitazone have expired, opening opportunities for generics.

What Challenges Affect the Market?

• Safety profile: Cardiovascular risks linked to rosiglitazone led to regulatory restrictions. Safety concerns for pioglitazone include edema, weight gain, and bladder cancer.
• Competition: Newer drug classes, such as SGLT2 inhibitors and GLP-1 receptor agonists, outperform TZDs in cardiovascular outcomes trials.
• Regulatory landscape: Restrictions and labeling changes impact drug marketing and prescription patterns.

What Is the Patent Landscape for Thiazolidinediones?

Patent Timeline for Key Drugs

Drug	Patent Filing Year	Patent Expiration	Key Patents	Status
Pioglitazone	1980s	2010s	Composition of matter, formulations	Patent expired; generics available
Rosiglitazone	1990s	2013	Compound patents, formulations	Patent expired; limited market presence
Novel Formulations	2000s-2010s	Varies	Extended patents on formulations, delivery methods	Some active; patent protections remain for specific formulations

Patent Strategies and Litigation

• Patent holders filed methods-of-use patents to extend exclusivity for combinations involving TZDs.
• Patent challenges have been filed in multiple jurisdictions, resulting in patent invalidations or expirations.
• New formulations (e.g., extended-release versions) have patents extending patent life cycles, with filings in countries like the US, Europe, and Japan.

Key Patent Expirations

• Pioglitazone: Most patents expired between 2010 and 2017, allowing generics.
• Rosiglitazone: Patents expired around 2013, although market presence declined due to safety issues.
• Presently, patenting activity focuses on formulations, delivery methods, and combination products.

How Do Regulatory and IP Policies Influence the Landscape?

• The expiration of key patents drives generic proliferation, decreasing prices and market entry barriers.
• Regulatory agencies such as FDA and EMA impose safety reporting requirements, influencing manufacturers’ R&D investments.
• Patent disputes and evergreening strategies impact innovation pacing and market exclusivity for newer formulations or combinations.

What Are Emerging Opportunities and Trends?

• Development of next-generation TZDs with improved safety profiles.
• Formulation patents seeking to extend patent life cycles.
• Combination therapies incorporating TZDs with new drug classes.
• Biomarker-driven patient stratification to optimize efficacy and safety.

Summary of Key Patent and Market Data

Attribute	Details
Patent expiry for generics	Pioglitazone: 2017 (most patents); rosiglitazone: 2013
Market size (2022)	USD 6.2 billion
CAGR (2023–2030)	3.2%
Major drugs	Pioglitazone, rosiglitazone (marketed/withdrawn)
Regulatory concerns	Cardiovascular risk (rosiglitazone), bladder cancer (pioglitazone)

Key Takeaways

• The TZD market is mature, with significant patent expirations leading to increased generic competition.
• Safety concerns affect the regulatory landscape and prescribing patterns.
• Innovation focuses on formulation improvements and combination therapies.
• Patent strategies include formulation patents and method-of-use patents to extend product lifecycle.
• Opportunities exist in developing safer derivatives and personalized medicine approaches.

FAQs

1. How has the patent expiration affected the availability of TZD drugs? Patent expiration has led to generic versions, reducing prices and broadening access.

2. What safety issues have impacted TZD market growth? Cardiovascular risks associated with rosiglitazone and bladder cancer risks linked to pioglitazone have constrained use.

3. Are there any new TZD compounds in development? No prominent new TZDs are in late-stage development. Focus has shifted to formulations and combination therapies.

4. How does regulatory policy influence TZD market prospects? Safety regulations and restrictions shape drug availability, prescribing practices, and R&D investments.

5. What future trends could impact the TZD market? Innovations in safer compounds, personalized treatments, and advanced drug delivery systems will influence market dynamics.

---

References

1. International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th edition. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html

2. U.S. Food and Drug Administration. (2013). Safety Announcement: FDA limits use of rosiglitazone-containing medicines. https://www.fda.gov/drugs/drug-safety-and-availability/fda-limits-use-rosiglitazone-containing-medicines

3. European Medicines Agency. (2018). Pioglitazone Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/actos-epar-product-information_en.pdf

4. patent databases and market reports as of 2022–2023.